

Format: Abstract

Send to

Phytother Res. 2008 Aug;22(8):1017-24. doi: 10.1002/ptr.2401.

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved.

Comelli F¹, Giagnoni G, Bettoni L, Colleoni M, Costa B.

Author information

Abstract

This study aimed to give a rationale for the employment of phytocannabinoid formulations to treat neuropathic pain. It was found that a controlled cannabis extract, containing multiple cannabinoids, in a defined ratio, and other non-cannabinoid fractions (terpenes and flavonoids) provided better antinociceptive efficacy than the single cannabinoid given alone, when tested in a rat model of neuropathic pain. The results also demonstrated that such an antihyperalgesic effect did not involve the cannabinoid CB1 and CB2 receptors, whereas it was mediated by vanilloid receptors TRPV1. The non-psychoactive compound, cannabidiol, is the only component present at a high level in the extract able to bind to this receptor: thus cannabidiol was the drug responsible for the antinociceptive behaviour observed. In addition, the results showed that after chronic oral treatment with cannabis extract the hepatic total content of cytochrome P450 was strongly inhibited as well as the intestinal P-glycoprotein activity. It is suggested that the inhibition of hepatic metabolism determined an increased bioavailability of cannabidiol resulting in a greater effect. However, in the light of the well known antioxidant and antiinflammatory properties of terpenes and flavonoids which could significantly contribute to the therapeutic effects, it cannot be excluded that the synergism observed might be achieved also in the absence of the cytochrome P450 inhibition.

PMID: 18618522 DOI: 10.1002/ptr.2401

[Indexed for MEDLINE]



MeSH terms, Substances

LinkOut - more resources

Full text links



Save items

Add to Favorites

Similar articles

The non-psychoactive cannabis constituent cann [Eur J Pharmacol. 2007]

A role for cannabinoid receptors, but not endogenous opi [Eur J Pharmacol. 2005]

Lack of analgesia by oral standardized cannabis extract [Anesthesiology. 2008]

Review Cannabinoids in the treatment of pain [Curr Opin Investig Drugs. 2002]

Review Cannabinoid transmission and pain perception. [Neurobiol Dis. 1998]

See reviews...

See all...

Cited by 14 PubMed Central articles

Related information

Recent Activity

Turn Off Clear

Antihyperalgesic effect of a Cannabis sativa extract in a r: PubMed

Cannabidiol inhibits paclitaxel-induced neuropathic pain thrc PubMed

Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of PubMed

The non-psychoactive cannabis constituent cannabidiol is an PubMed

Neuropathic orofacial pain: cannabinoids as a therapeutic PubMed

See more...

You are here: NCBI > Literature > PubMed

Support Center

GETTING STARTED

- NCBI Education
- NCBI Help Manual
- NCBI Handbook
- Training & Tutorials
- Submit Data

RESOURCES

- Chemicals & Bioassays
- Data & Software
- DNA & RNA
- Domains & Structures
- Genes & Expression
- Genetics & Medicine
- Genomes & Maps
- Homology
- Literature
- Proteins
- Sequence Analysis
- Taxonomy
- Variation

POPULAR

- PubMed
- Bookshelf
- PubMed Central
- BLAST
- Nucleotide
- Genome
- SNP
- Gene
- Protein
- PubChem

FEATURED

- Genetic Testing Registry
- GenBank
- Reference Sequences
- Gene Expression Omnibus
- Genome Data Viewer
- Human Genome
- Mouse Genome
- Influenza Virus
- Primer-BLAST
- Sequence Read Archive

NCBI INFORMATION

- About NCBI
- Research at NCBI
- NCBI News & Blog
- NCBI FTP Site
- NCBI on Facebook
- NCBI on Twitter
- NCBI on YouTube
- Privacy Policy